![Caryn Peterson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Caryn Peterson
Direktör/Styrelseledamot på
ASPEN NEUROSCIENCE, INC.
Förmögenhet: 38 418 $ per 2026-09-30
Profil
Ms. Caryn L.
Peterson is an Independent Director at Aspen Neuroscience, Inc., a Chief Development Officer at Gossamer Bio, Inc. and a Chief Executive Officer at Alevium Pharmaceuticals, Inc. She is on the Board of Directors at Aspen Neuroscience, Inc. Ms. Peterson was previously employed as a Vice President-Regulatory Affairs by OncoSec Medical, Inc., a Vice President-Regulatory Affairs by Syndax Pharmaceuticals, Inc., a Managing Partner by DSC Associates LLC, a Vice President-Regulatory Affairs by FeRx, Inc., an Associate Director-Regulatory Affairs by Amylin Pharmaceuticals, Inc., a Principal by Hybritech, Inc., and a Vice President-Regulatory Affairs by Ascenta Therapeutics, Inc.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
GOSSAMER BIO, INC. 0,05 % | 2026-08-24 | 3 242 ( 0,05 % ) | 38 418 $ | 2026-09-30 |
| 2026-10-29 | 0 ( -.--% ) | - $ | 2026-09-30 |
Aktiva positioner av Caryn Peterson
| Företag | Position | Start |
|---|---|---|
| GOSSAMER BIO, INC. | Företagsledare/Principal | - |
| ASPEN NEUROSCIENCE, INC. | Direktör/Styrelseledamot | 2021-05-01 |
Alevium Pharmaceuticals, Inc. | Verkställande Direktör | 2009-06-01 |
Tidigare kända positioner av Caryn Peterson
| Företag | Position | Slut |
|---|---|---|
DSC Associates LLC | Grundare | 2018-01-01 |
| SYNDAX PHARMACEUTICALS, INC. | Generell Rådgivare | 2018-01-01 |
FeRx, Inc.
 FeRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and distributes magnetic technology for the treatment of cancer | Generell Rådgivare | 2004-01-01 |
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Generell Rådgivare | 1997-01-01 |
Hybritech, Inc.
 Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Provides prostate diagnostic testing services | Företagsledare/Principal | 1989-01-01 |
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
59
Första gradens relationer
10
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 10 |
|---|---|
Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Hybritech, Inc.
Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Provides prostate diagnostic testing services | Commercial Services |
Syndax Pharmaceuticals, Inc.
 Syndax Pharmaceuticals, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company | Health Technology |
OncoSec Medical, Inc.
 OncoSec Medical, Inc. BiotechnologyHealth Technology Engages in discovery and development of novel immunotherapeutic products for immuno-oncology treatment | Health Technology |
Ascenta Therapeutics, Inc.
 Ascenta Therapeutics, Inc. BiotechnologyHealth Technology Discovers and develops medicines for cancer | Health Technology |
FeRx, Inc.
FeRx, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and distributes magnetic technology for the treatment of cancer | Health Technology |
Alevium Pharmaceuticals, Inc. | |
DSC Associates LLC | |
Gossamer Bio, Inc.
 Gossamer Bio, Inc. Pharmaceuticals: MajorHealth Technology Engages in developing and commercializing therapeutics for immunology, inflammation and oncology diseases | Health Technology |
Aspen Neuroscience, Inc.
 Aspen Neuroscience, Inc. BiotechnologyHealth Technology Operates as a clinical-stage regenerative medicine biotechnology company and develops autologous induced-pluripotent stem cell | Health Technology |
